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ABSTRACT
CHLAMYDIA;
UNIVERSAL VS SELECTIVE SCREENING 
By
Veraeal Y. Glispie
Women, age 20 to 39, attending three family planning clinics within a Michigan health 
department, were screened for Chlcmydia trachomatis. A nucleic acid hybridization test 
(Gen-Probe) was used to collect cervical specimens for seven consecutive months. A 
chlamydia risk assessment form, using Michigan Department of Community Health's 
selective screening criteria, was used to determine the client's risk group. A chi-square test 
with Yates correction was used for data analysis. The prevalence rates of high and low 
risk groups were compared with no significant difference (p = .18). The prevalence rates 
were \2.%Vo in Site A; 1.7% in Site B; 1.7% in Site C; and the mean prevalence rate was 
3.0%. CDC's 5% prevalence rate, and NCchigan's 1994 local out county, and state 
prevalence rates of 7.9% and 5.08% respectively, were used as guidelines for determining 
high risk populations. Universal screening was recommended and instituted for Site A, and 
selective screening was continued in Sites B and C.
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CHAPTER 1 
INTRODUCTION
Chlamydia trachomatis (chlamydia) is the most common bacterial sexually transmitted 
disease (STD) in the United States and causes more than four million infections annually 
(U.S. Department of Health and Human Services, 1994). Chlamydia has been described as 
the silent STD. Approximately 70% of clients with chlamydia are asymptomatic, and the 
infection may persist for up to 15 months. Serious complications associated with 
chlamydia make annual routine screening, for high risk populations, imperative. The most 
frequent complications of untreated chlamydia are pelvic inflammatory disease (FID) and 
infertility (Primary Care Update, 1994). An estimated 15% to 40% of women with 
untreated chlamydia develop PID. Twenty percent of women with PED become infertile, 
18% develop prolonged pelvic pain, and 9% will have one or more ectopic pregnancies 
(Kllis, Black, Newhall, Walsh, & Groseclose, 1995).
Several research studies across the country have documented the benefit of universal 
chlamydia screening for high risk populations. Although the Michigan Department of 
Community Health (MDCH) (formally the Nfichigan Department of Public Health) made 
chlamydia a reportable disease in 1992, they have only allocated fimds for selective or high 
risk screening. MDCH’s high risk criteria are a) being less than 20 years of age, b) having
a history of STD in the past six months, c) having multiple partners, d) having a partner 
with multiple partners, e) having a new partner in the past six months, f) having a 
discharge or mucopurulent cervicitis (MPC), and/or g) having a ftiable cervix (MDCH, 
1992). Instituting selective screening was a major step in the identification and early 
treatment of chlamydia, but the women who are not selected for testing may be at 
comparable risk. Universal screening could make the difference between spending an 
average of $12 per client for screening and treatment, as opposed to spending hundreds of 
dollars on emergency, inpatient, and possibly surgical treatment.
Although MDCH has identified several high risk screening criteria, the client's risk may 
not always be accurately determined during an assessment interview. The client may be 
reluctant to acknowledge having more than one sex partner, recent treatment for an STD, 
or that her partner had more than one sex partner. Situations also occur in which the client 
may not be aware that her partner has more than one sex partner or that he had recently 
been treated for an STD. Therefore, unless the client is less than 20 years old or 
symptomatic, she may not be selected for screening.
Chlamydia testing is done by using culture or nonculture methods to test specimens 
obtained from the endocervicai os. Cultures cost $25 to $50, with results returned in 
three to seven days. The nonculture test, which is the screening method used by most 
clinics, costs $8 to $12, with results available in three to four hours (Drolet, 1992). Due to 
the high cost of chlamydia screening, most providers do not routinely offer testing. Failure 
of providers to screen routinely for chlamydia leaves asymptomatic women vulnerable to 
developing unnecessary complications from this infection. Researchers have suggested
that preventing the complications of chlamydia could save states millions of health care 
dollars in outpatient and inpatient care for treatment of PID, ectopic pregnancies, or other 
complications. First year savings were estimated at six million dollars with five year 
savings reaching more than $60 million (U.S. Public Health Service, 1991).
In the three-year period of 1992-1994, two family planning clinics in an urban health 
department selectively screened 1,077 females using MDCH protocol. Of those 1,077 
female clients, 16 to 39 years of age, 118 tested positive for chlamydia. This represented a 
16% prevalence rate at Site A, 9.7% at Site B and a mean prevalence rate of 11% (Wayne 
County Department of Health, 1994). The Centers for Disease Control (CDC) (1993) 
rates any prevalence > 5% as indicative of a high risk population. These retrospective data 
obtained fi'om the local health department did not include data on the low risk population, 
and specific descriptive data were not available. The data did, however, provide good 
background information and were the basis for this study.
The National Health Promotion and Disease Prevention Objectives for the Healthy 
People 2000 initiative include a focus on reducing the spread of STD's. Effective methods 
of early identification and treatment of chlamydia were among those objectives (U.S. 
Public Services, 1991). After MDCH made chlamydia a reportable disease in 1992, it 
became imperative that all health care professionals serving sexually active clients take 
chlamydia seriously. The Michigan Department of Community Health (1994) reported 288 
cases of chlamydia in 1992, 4,783 cases in 1993, and 17,688 cases in 1994. It is not clear 
if the previous figures represent a true increased prevalence or if th ^  reflect increased 
screening and reporting practices in NCchigan. Nevertheless, rates of 9.7% and 16% in
these family planning clinics were above the mean prevalence rate of 5.1% for Michigan 
family planning clinics in 1994 (MDCH, 1995). In order to evaluate the effectiveness of 
the present screening criteria, this study compared the prevalence rates of the low risk 
groups to those of the high risk groups in three health department family planning clinics. 
It used the prevalence rates found in each risk group to determine whether universal 
screening or selective screening protocols would be more appropriate for use in these 
clinics.
The purpose of this study was to determine if the selective screening protocol, 
currently used by the urban health department, was adequate for screening their clinic 
populations or if universal screening would be preferable. Despite multiple studies on high 
risk criteria for chlamydia, researchers remain unable to establish reliable positive 
predictors for this infection and recommend universal chlamydia screening for high risk 
populations (Phillips, Aronson, Taylor, & Safran, 1987). CDC, also, recommends sentinel 
or periodic universal screening to monitor the prevalence of chlamydia in target 
populations.
CHAPTER 2 
LITERATURE AND THEORY
Chlamydial infections have become the most common sexually transmitted disease in 
the United States. Although the cost of early treatment is minimal, the cost of testing has 
prevented widespread screening (Weinstock et al., 1992). In the 1980's, multiple studies 
were conducted to determine risk factors that would serve as positive predictors for 
chlamydia, and to determine which nonculture test shows the highest specificity and 
sensitivity for this bacterial infection. The higher the specificity of the nonculture test the 
more likely a negative result indicates the infection is not present; thus, the test has a 
higher rate of true negatives and a lower rate of false positives. The higher the sensitivity 
of the nonculture test the more likely a positive result indicates the infection is present; 
thus the test has a higher rate of true positives and a lower rate of false negatives. In 
addition, reliable positive predictors would make selective screening an alternative to the 
higher cost of universal screening. In spite of the many studies done on chlamydia, 
researchers have been unable to establish highly reliable predictors for high risk 
populations. Thus far, the nmjor savings have been by the use of nonculture chlamydia 
testing for mass screenings, reserving the more costly culture test for cases with legal 
implications.
The literature review showed three basic types of studies. These were universal 
screenings, selective screening, and cost benefit studies. Universal screening studies 
focused on the benefit of screening all clients in high risk populations. Selective screening 
studies focused on screening only clients meeting predetermined high risk criteria as a cost 
reduction measure. Cost benefit studies compared the direct and indirect cost of screening 
and treatment when needed. The direct cost related to the mtpense of screening and 
treatment of uncomplicated cases, and the indirect cost related to complications and 
treatment for untreated chlamydial infections. Key variables, which included the lower end 
of the screening test's sensitivity, the direct and indirect cost of testing and treatment, and 
the population's prevalence rate for chlamydia, were analyzed to determine at what 
prevalence rate the cost of universal screening would outweigh the cost of treating 
complications from undetected cases. Betty Neuman’s Systems Theory was used as a 
basis for examining risk factors and prevalence rates of chlamydia. Her concepts of 
“Primary and Secondary Prevention as Intervention” (Neuman, 1995) are discussed as 
they relate to the importance of screening for chlamydia.
UmYgsal^ grgeniog
Dr. Russell Phillips (1987), from Harvard Medical School, along with several other 
researchers recommended routine or universal screening in populations with a prevalence 
rate above 6% to 7%. Universal screening was recommended because a) 60% to 80% of 
clients who had chlamydial infections are asymptomatic, b) there is a high probability of 
obtaining inaccurate histories relating to the client's sexual partner(s), and c) highly reliable 
risk factors have not been established (Woolard, Canp, Larson, & Hudson, 1989). The
relationship of prevalence to screening protocols are discussed in conjunction with cost 
benefit analysis. Several universal screening studies were done in urban family planning 
and STD clinics. Included in this literature review were studies conducted in Midwestern 
USA, Ohio, California, Virginia, Colorado, New York, and Canada.
In the early 1980's, a chlamydia study was conducted by Woolard et al. (1989) at a 
NCdwestem university campus (Table 1). The result of this study showed a prevalence rate 
of 12.6%, using Abbott's Chlamydiazyme nonculture test. CDC reports nonculture 
tests such as Chlamydiazyme to have a sensitivity of 67% to 95% and a specificity of 97% 
to 99%. Of the 419 females who were screened, 53 of them tested positive for chlamydia. 
Limitations of this study were cited as having a high possibility of a) false-positive results 
with the use of Chlamydiazyme nonculture test in low prevalence populations; and b) 
inaccurate historical data reported by the client, related to her own or her partner(s) 
history of past STD's, and the number of partners the client or her partner(s) have had in 
the past year. This study concluded that due to the high incidence of asymptomatic women 
found to have chlamydia, routine testing is strongly recommended in most college based 
family planning clinics.
A study conducted at Columbus Health Department screened 60,000 to 70,000 
females annually for three years. Reports fi’om this study showed a decrease in prevalence 
fi’om 8.8% in 1985, to 5% in 1988 (Johnson, 1992). Although a nonculture test was used 
in this study, the type of test, sensitivity, and specificity were not reported. Johnson states 
that this study and others were limited by unsatisfactory collection of endocervicai cells
Table 1.
Chlamydia: Univsrsal Sçregning Studies
DATE OF 
STUDY/ 
AUTHOR
LOCATION TEST POS RATE TEST USED SEN SPEC CONCLUSIONS
1980's 
Woolard 
et al. (1989)
Midwestern
University
419 53 12.6% Chlamydiazyme
(Abbott)
•67%
to
95%
•97%
to
99%
High % of asymptomatic clients & 
inaccurate hx's limits predictability for 
chlamydia. Routine (universal) screening 
was recommended for college women.
1985-88 
Johnson, M. 
(1992)
Columbus 
Health Dept.
60,000-
70,000
x3yrs
ukn
8.8% 
in 1985 
to 5% 
in 1988
unspecified
nonculture
•67%
to
95%
•97%
to
99%
Widespread universal screening decreased 
the prevalence rate by 43% in 3.5 yrs. 
Replication of this project, especially for 
teen & Black populations recommended.
1987-88 
Weinstock 
et al. (1992)
San Francisco 1,348 124 9.2% MicroTrak
DFA
**
61%
98%^ Recommended universal screening in high 
risk populations and selective screening for 
use in low risk populations.
1987-88 
Johnson, B. 
et al. (1990)
Virginia 
Commonweal 
th University
1,458 133 9% MicroTrak
DFA
•61%
to
90%
98%^ No current selective screening model yet 
proven to be reliable. Verification of this or 
other study model needed before selective 
screening is eflective for use in high risk 
populations.
Note. ^Manufacturer's or CDC's data ** Data reported in study Pos = Positive Sen = Sensitivity Spec = Specificity DFA = direct 
fluorescent antibody ELA = enzyme immunoassay
(table 1 continues)
Table 1. (continued)
Chlamydia: Universal Screening Studies
Date of
Study
AUTHOR
LOCATION TEST POS RATE TEST USED SEN SPEC CONCLUSIONS
1988 
Zimmer­
man et al. 
(1990)
Colorado
Springs
2,437 
males - 
females
419 17% MicroTrak
DFA
**
90%
**
98%
20.5% positives identified via contact- 
tracing, 59.7% via routine screening, & 
19.8% presented to clinic with 
symptoms.
Increased reporting would facilitate 
contact follow-up
1988
Holmes
etal.
(1993)
New York 
City
Correctional
Institution
101 27 27% Unspecified 
cell culture
**
80%
*
nearly
100%
Combination of 3 high risk indicators 
only identified 70% of women positive 
for chlamydia. Recommend routine 
screening for all inmates on admission.
1980-81 
Embil & 
Pereira 
(1985)
Halifax,
Canada
355 29 8.2% Unspecified 
cell culture
*
80%
*
nearly
100%
All clients screened were asymptomatic. 
Chlamydia was much more prevalent in 
women under 25 years. Chlamydia was 
also higher in women with multiple 
partners.
1989-90 
Sellers 
et al. 
(1992)
McMasters
University
Ontario
1,002 70 7% Chlamydiazyme
ElA
(Abbott)
**
78.6% *97%
to
99%
Use of 4-5 predictors was effective for 
screening low prevalence populations. 
Saving gained in reduced cost of 
selective screening are lost with the 
increased cost of treatment for missed 
cases in high prevalence populations.
necessary for proper analysis. An average of 15% to 30% of unsatisfactory specimens may 
be found with widespread testing. To reduce this problem, the Columbus project 
sponsored in-service training to participating providers. Johnson concluded that the 
widespread universal screening done in the Columbus Health Department decreased the 
prevalence rate by 43% in about three years. Therefore, he recommends the replication of 
this project wherever possible, especially in high risk, teen, and predominately Black 
populations.
During a 1987-1988 study in San Francisco, Weinstock, Bolan, Kohn, Balladares, 
Back, and Oliva (1992) screened 1,348 females for chlamydia. With 124 women testing 
positive, the prevalence rate was 9.2%. A direct fluorescent antibody test, with a 
sensitivity of 61% as compared to 99% with cultures, was reported as a limitation of this 
study. Although no additional data were presented, the use of cytobrushes to collect 
endocervicai specimens was felt to improve the sensitivity of the nonculture test. 
Weinstock et al. felt that due to the low sensitivity of the nonculture test, universal rather 
then selective screening should be used in high risk populations to increase the numbers 
screened, thus increasing the number of positive cases detected.
In a study conducted at Virginia Commonwealth University, 1,458 females were 
screened, and 133 tested positive for a prevalence rate of 9% (Johnson, Poses, Fortner, 
Meier, & Dalton, 1990). A direct fluorescent antibody (DFA) nonculture test was also 
used in this study, but no sensitivity or specificity data were reported. Since the cost of 
universal screening was a major concern for the Virginia Commonwealth University 
Clinic, a selective screening model designed to identify high, moderate, and low risk
10
clients was developed. The researchers admit that models so far have not been reliable but 
feel that one will be developed in the foreseeable future.
In Colorado Springs, a study o f2,437 males and females reported 419 positive tests 
and a prevalence rate of 17% for chlamydia (Zimmerman, Potterat, Dukes, Muth, 
Zimmerman, Fogle, & Pratt, 1990). In this study the NCcroTrak DFA's sensitivity was 
reported as 90%. Contact-tracing was responsible for identifying 20.5% of the positive 
chlamydia cases, 59.7% were identified by routine screening, and only 19.8% of clients 
presented to the clinic with symptoms. Zimmerman et al. advised that increased reporting 
of chlamydia cases to public health ofBcers would facilitate contact follow-up.
A 1988 study, conducted at New York City's Rikers Island Correctional Institution, 
found that of 101 females screened, 27 of them tested positive, with a prevalence rate of 
27%. An unspecified cell culture with a sensitivity of 80% was used in this study. Since 
only 70% of the infected inmate population would have been identified using selective 
screening criteria, testing or offering presumptive treatment to all new female inmates was 
suggested (Holmes, Safyer, Bickell, Vermund, Hanf^ & Phillips, 1993).
Canadian studies have shown similar findings During 1980 and 1981 in Halifax, 355 
females were screened, and 29 of the women tested positive for chlamydia. The 
prevalence rate was 8.2%. Chlamydia was found to be more prevalent in women less than 
25 years old and higher in women with multiple partners (Embil & Pereira, 1985).
In a study conducted at the McMaster University Student Clinic in Ontario, 70, out of 
1,002 females screened, tested positive, thus having a prevalence rate of 7%. Abbott's 
Chlamydiazyme enzyme immunoassay (ELA) nonculture test was used and reported to
11
have a sensitivity of 78.6% in that study. Canadian researchers agreed that in low 
prevalence settings, selective screening offered an efScient strategy compared with 
universal screening. Whereas in high prevalence settings, the increased costs incurred by 
treating the sequelae among missed cases reduced any savings associated with a selective 
screening program. The opportunity cost principle recognizes the existence of other cost- 
effective services that compete for women’s health resources. It also recognizes that the 
limited resources of health care systems were the main forces propelling efforts to 
efficiently screen women for this disease (Sellers et al., 1992).
Universal screening studies in these urban areas all showed that despite the individual's 
risk factors, when nonculture tests were used for routine screening, the prevalence rates 
ranged fi’om 5% to 27% with a mode rate of 8% to 9%. Several high risk indicators for 
chlamydia were identified in all o f the studies; but no single indicator was consistently 
found to be a determinant for the presence of the chlamydial infection. All studies were 
limited by the use of convenience samples as opposed to random sampling. Using only 
clients who came into the clinics for services may not have produced an accurate sample 
of the target population at large.
Selective Screening
Multiple selective screening studies have been conducted to identify specific high risk 
indicators of chlamydia. Finding one or more reliable indicators would allow providers to 
screen only those clients at risk for the infection, thereby saving the cost of routinely 
screening all clients (Addis, Vaughn, Holzhueter, Bakken, & Davis, 1987). Researchers 
looked at several high risk factors identified in universal screening studies and used them
12
to develop selective screening protocols. Although both culture and nonculture tests were 
used in various studies for purposes of comparison, this literature review primarily focused 
on prevalences obtained using nonculture tests (Table 2).
Between 1980-1982, a study was conducted at a University of California / Los 
Angeles (UCLA) Student Health Center. Six hundred and thirty-eight females, with some 
predetermined high risk factors, were selectively screened for chlamydia. Using the Eagle 
cell culture, 42 students tested positive, and the prevalence rate was determined to be 
6.6%. Risk factors for those testing positive included a mean age of 23.5, multiple 
partners, a partner with a recent history of urethritis, and/or the use of contraceptives. No 
associations were found between a positive chlamydia test and a history of testing positive 
for sexually transmitted diseases including gonorrhea, chlamydia, syphilis, or genital 
herpes. Nor was there any association with Trichomonas or GardnerelUr, dyspareunia; 
abnormal vaginal discharge, burning, or odor, dysuria; or cervicitis on examination by 
clinicians. Although there are few reliable clinical markers that would identify positive 
chlamydia cases, clients with multiple partners and partners with nongonococcal urethritis 
(NGU) were the most common indicators in this UCLA clinic population (Weismeier, 
Lovett, & Forsythe, 1984). No specific recommendations were made regarding universal 
versus selective screening in this study, but the previous statement regarding multiple 
partners and NGU gives some direction in support of selective screening.
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Table 2.
Chlamydia: Selective Screening Studies
UCLA 
Student Health 
Center, 
1980-82 
(Wiesmeier 
et al., 1984)
Seattle Public 
Health Clinic, 
(unspecified year) 
(Handsfield, 
et al., 1986)
Wisconsin 
F.P. Clinic, 1985 
(Addiss et al., 
1987)
Milwaukee 
Community & 
Urban Health 
Center, 1986 
(Addiss et al., 
1990)
New York State 
Public Health 
Clinics, 
1985-86 
(Han et al., 1993)
San Diego 
County Public 
Health 
Centers, 
1989-93 
(CDC, 1994)
# Tested & 
Age Range
638
Unspecified
1,059 
> 14yrs
335 
14-37 yrs
751 
13-49 yrs
1,531 
16-27 yrs
11,044
n/a
Prevalence
Rate
6.6%
(42)
9.3%
(98)
10.7%
(36)
12.4%
(93)
13.6%
(208)
10.0% in 
1989 to 
1.9% in 1993
Test(s) used Eagle Culture MicroTrak
DFA
DFA
Chlamydiazyme
ElA
MicroTrak - 
DFA 
&
ElA
MicroTrak-DFA 
Chlamydiazyme - 
ElA by Abbott 
(A-EIA)
MicroTrak - 
EIA(M-EIA) 
3/91-3/93
Sensitivity n/a ♦DFA 92% ♦♦89%-90 ♦♦DFA - 77.4% 
♦♦A-EIA - 83.9%
♦DFA - 92% 
♦A-EIA 83.9%
♦M-EIA 93%
Specificity n/a ♦DFA 98% ♦♦97%-98% ♦♦DFA - 96.8% 
♦♦A-ElA-97%
♦ DFA - 98% 
♦A-EIA 97%
♦M-EIA 99%
Note, n/a = not assessed in this study NR = no relationship found in this study ♦ Manufacturers or CDC data ♦♦data reported in t lis study
♦•^Screening criteria recommended at conclusion of this study Direct fluorescent antibody (DFA) Enzyme immunoassay (ElA) 
Nongonococcal urethritis (NGU)
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Table 2. (continued)
Chlamydia: Selective Screening Studies
(Wiesmeier 
etal., 1984)
(Handsfield 
etal., 1986)
(Addiss et al., 
1987)
(Addiss et al., 
1990)
(Han et al., 1993) (CDC, 1994)
Age ***
mean age 23.5
<24 yrs*** 
mean age 21.8 
12.4%
15% <20 yrs*** 
16%<20 
6.7% >20
<20 yrs 19.65 
>20 yrs 9.5 <20 yrs 17.9% 
12.3%>20yrs 
mean age 21
***
<20 yrs 8.4%
Recent new 
partner
n/a 17.3%*** 
< 2 months
17.5%*** ***23.1% 
< 3 months
n/a ***
< 3 months
Hxof >1 sex 
partners or partner 
with>l partner 
in the past 
2 months to 1 yr
30% •**
8.3% 0-1 partners 
*** >2 partners 
past two months 
15.6%
29.2%*** *** >1 partner 
<3 months 
25.3%
>1 pastyr 
21.6%
*** >1 partner 
<6 months 
12.7% 
none or one 
10.5%
***
> partner 
< 3 months
Partner with hx of 
NGU < 30 days
***33% n/a 100% *** ***28.1% n/a n/a
Nonbarrier
methods
n/a ***
25.8%
n/a none, rhythm or 
withdrawal 13.9%
6% A A A
Hx of GC NR NR LR ***Partncr - GC 
<30 days 40%
NR n/a
Current GC 0.8% 1.2% 0.3% ***36.4% NR n/a
MPC NR 23.3%*** ***40% * * *
mucoid 11.3% 
purulent 25.8%
***
17.7%
* * *
15 (tabic 2 continues)
Table 2 (continued)
Chlamydia: Selective Screening Studies
(Wiesmeier 
etal., 1984)
(Handsfield, 
etal., 1986)
(Addiss et al., 
1987)
(Addiss et al., 
1990)
(Han et al., 1993) (CDC, 1994)
Friable cervix n/a 19%*** ***26.5% ***20.9% n/a n/a
Symptomatic 6.6% 8.7% 11.3% n/a ***16.9% n/a
Inflammation on 
Pap smear
n/a n/a
Inflammatory 
changes on 
current Pap 
42.9% last Pap 
28.2%
> 5 lymphocytes 
on 400x field 
22.0%
<5 = 11.5% 
S+-4+ PMN 
29.9%
0.2+ 10.= 9%
«««
25% pos in one 
clinic 
13%negin same 
clinic
n/a
Conclusions Few reliable clinical 
markers that could 
identified positive 
cases. Multiple 
partners & partners 
with NGU were the 
most common 
indicators in this 
university 
population
No single risk 
factor identified. 
Which supports 
other studies 
recommendations 
for universal 
screening. Selective 
screening 
recommended for 
women with > 2 
risk factors*** as a 
cost-effective 
means for early 
detection of 
chlamydia
No single 
symptom or 
cluster of 
symptoms were 
reliable 
predictors of a 
positive DFA. 
Major finding: 
client's reason 
for visit not 
predictive of 
positive test. 
Recommend all 
clients be 
assessed for risk.
No one variable 
had sufficient 
predictive value 
for use as only 
criterion to 
selectively screen 
this population for 
chlamydia. 
Proposed criteria 
would screen 43% 
of clients & 
identify 71% of 
infections.
Selective screening 
is useful in 
directing limited 
testing funds to 
those most likely 
to be infected.
Recommends 
universal 
screening for 
all initial 
exams and 
selective 
screening for 
annual and 
other visits
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A Seattle public health clinic universally screened 1,059 females to determine high risk 
fectors. Using the MicroTrak DFA nonculture test, 98 clients tested positive for a 
prevalence rate of 9.3%. Significant characteristics of those testing positive included 
a) being < 24 years of age, b) two or more s&oial partners in the past two months, 
c) a recent new partner, d) an abnormal vaginal discharge, e) a mucopurulent cervicitis, 
f) a fiiable cervix, and g) cervical ectopy (ectropion). Nonsignificant predictor 
characteristics for chlamydia in this study included race, age at the onset of sexual 
intercourse, recent history of STD’s, complaints of vaginal itching or irritation, urinary 
tract symptoms, lower abdominal pain, or pain with sex. The study concluded that no 
single risk factor was identified as a positive predictor for chlamydia, which supports other 
studies' recommendations for universal screening. However, as a cost-saving measure, 
Handsfield, Jasman, Roberts, Hanson, Kothenbeutel, and Stamm (1986) recommended 
selective screening for women with two or more of the risk factors identified in this study.
In a study conducted at four Wisconsin family planning clinics, 335 females were 
selectively screened. DFA and Chlamydiazyme ELA nonculture tests, with a sensitivity of 
89% to 90% and a specificity of 97% to 98% respectively, resulted in 36 positive tests and 
a prevalence of 10.7%. Risk factors similar to those used in previous studies were used to 
determine the predictive criteria for this study. The major correlated factors included 
having a new sexual partner, a partner with urethritis, a partner with more than one 
partner, a fiiable cervbc, a mucopurulent discharge, or being less than 20 years old. A 
likely relationship between a current history of gonorrhea and a current positive 
chlamydial infection was found in this study. It also noted that younger women were more
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prone to cervical ectropion than older women. Cervical ectropion is a condition in which 
more columnar epithelial cells are exposed and thus makes women < 24 years old more 
susceptible to chlamydia (Addiss, Vaughn, Holzhueter, Bakken, & Davis, 1987) The 
client's reason for visiting the clinic was not found to be predictive of chlamydia. Nor was 
there any relationship found between chlamydia and the client's race, educational level, 
martial status, history of STD's (other than gonorrhea )^, genitourinary related symptoms, 
or the use of oral contraceptive pills (OCP's). No single symptom or cluster of symptoms 
was found to be a reliable predictor of chlamydia. Addiss et al., however, recommended 
high risk selective screening, that would detect 89% of clients with chlamydia by testing 
only 58% of the clinic population.
In 1986, two Nfilwaukee, Wisconsin family planning clinics conducted a study. 
Universal screening was done on 751 females who were assessed as having similar high 
risk factors. Ninety-three of them tested positive, for a prevalence of 12.4% using the 
DFA and 13.1% using the ELA The DFA’s had a sensitivity of 77.4%, resulting in 22.6% 
false negatives; and a specificity of 96.8%, resulting in 3.2% Alse positives and a 
predictive value positive (PVP) of 77%. EIA had a sensitivity of 83.9% (thus a false 
negative rate of 16.1%), a specificity of 97% (thus a false positive rate of 3%), and a PVP 
of 80%. When high risk criteria were used including a) cervicitis; b) positive GC; c) 
partner with NGU, epididymitis, or GC within the past 30 days; and d) more than one 
sexual partner, or a new partner within the past 3 months, 43% of the 751 clients were 
identified as high risk and tested. This resulted in identifying 71% of clients actually having 
a positive chlamydia test. Although Addiss, Vaughn, Golubjatnikov, Pfister, Kurtycz, and
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Davis (1990) recognize selective screening as an effective cost saving alternative, they still 
recommend universal screening for adolescents and women seen in high risk areas, if 
resources are available.
A study conducted in ten clinics outside New York City screened 1,531 females for 
chlamydia. Positive tests were reported for 208 of those tested, yielding an overall 
prevalence rate of 13.6% (Han, Morse, Lawrence, Murphy, & Hipp, 1993). A prevalence 
of 17% was reported for the eight high risk family planning and STD clinics. In the two 
low risk private and college clinics, the prevalence rate was 5.6%. Six high risk indicators 
observed in this study were clients less than 20 years old, multiple partners, the use of 
OCP’s, MPC, inflammation on Pap smear, and symptomatic reason for their clinic visit.
No relationship with race or history of other STDs was found. The authors of this study 
believed that the relationship between use of OCP's and chlamydia was explained by the 
tendency of estrogen and progesterone to foster the growth of chlamydia and an increase 
of ectropion in women using OCP's. This study also discussed the possibility that the use 
of antibiotics, vaginal creams, and douches may have masked the presence of chlamydia, 
thereby increasing the chances of obtaining false negative results. Han et al. state that 
selective screening is useful in directing the limited testing funds to clients most likely to 
be infected.
A five year study, conducted in six San Diego County public health centers, found that 
after screening 11,044 females during routine initial or annual visits, the prevalence 
decreased fi’om 10.0% in 1989, to 1.9% in 1993. Ninety-one percent of those screened 
were asymptomatic. At the start of the study, fi'om March 1989 through February 1991,
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the Ortho Diagnostic Systems enzyme-linked immunoabsorbent assay (ELISA) test was 
used for screening. Although no reason was documented for the change in collection and 
testing methods, in March of 1991 the MicroTrak EIA was used to complete the testing. 
No sensitivity or specificity data were documented in this report. The high risk indicators 
in this study were being of the Black race and being less than 20 years old. Other 
indicators included having multiple partners or a new partner in the past three months, 
using a non barrier method of contraception, and having mucopurulent cervicitis. The 
results of this study led to the implementation of policy by the California OflBce of Family 
Planning in August 1993, which requires universal screening on all initial examinations and 
selective screening for annual and other clinic visits (CDC, 1994).
Selective screening studies have consistently identified several high risk factors that 
were predictive of a chlamydial infection. The one factor that consistently showed the 
highest risk was women less than 20 years old. Other factors associated with high risk 
were having multiple partners or a new partner in the past three months, a partner with 
multiple partners, single status, abnormal vaginal discharge, cervicitis, failure to use 
condoms, a recent history of gonorrhea, and symptoms of an urinary tract infection. 
However, no single fiictor or group of risk factors were shown to be highly reliable 
predictors in replicated studies. As a result, most clinics adopt a set of high risk 
characteristics identified in their study of choice and accept the selective screening 
predictive value "positive" of 77%, to save the cost of universally screening all clients.
The weakness of this strategy is that 23% of clients with chlamydia are missed, and many 
go on to have long term complications from an untreated infection.
2 0
Cost Versus Benefit
Cost benefit studies were done primarily to determine at what prevalence rate the cost 
of selective or universal screening pays for itself. Although the cost of screening in dollars 
is an inescapable factor, providers should not ignore the serious consequences this STD 
can inflict on a very vulnerable population. Statistics show that within five years of an 
infection, many clients with untreated chlamydia suffer fi'om PID resulting in chronic 
pelvic pain (due to adhesions), infertility, and/or complications of pregnancy (Hillis et al., 
1995). These facts support the Phillips et al. (1987) study which recommends routine 
screening in high risk populations, defined by CDC as a prevalence > 5%.
A 1984 study conducted in Boston determined the break-even prevalence rate for 
nonculture tests to be 7% and 14% for culture tests, when direct and indirect costs of 
treatment were considered (Table 3). The cost of using nonculture tests such as the DFA 
and EIA rapid test was $15, and treatment with doxycycline was $2. The sensitivity and 
specificity for DFA and EIA reported in this study were 80% and 98% respectively. Only 
the cost of the test and the medications were considered because the other costs would 
normally be included in the cost of a routine family planning visit. Phillips, Aronson, 
Taylor, and Safi'an (1987) determined that the cost of screening and treatment will pay for 
itself if the prevalence rate is greater than 7%.
Neddleman and Jones (1988) evaluated the prevalence rate of a college population to 
be 7.9%, and the cost-eflfectiveness prevalence rate to be 7.94%. A direct antigen 
nonculture test, with a sensitivity of 53% and a specificity of 96%, was used in this study.
21
Tables.
Chlamydia: Cost Versus Benefit Studies
Location 
Dale 
Type clinic 
Number 
screened
Break -even 
prevalence 
rate
Rate
Pos
Test
used
Sen Spec Cost of test 
&
Treatment
Conclusions
Phillips et al. 
(1987)
Boston
1984
7% 
nonculture 
14% culture
7% DFA
EIA
80%**
80%**
98%**
98%**
Nonculture 
test - $15 
Meds $2
Only the cost of test and 
meds were considered. 
Other costs are charged 
to a routine F.P. visit. 
Thus if prevalence rate 
>7, screening & tx pays 
for itself
Neddleman 
& Jones 
(1988)
1985-6 
college clinic 
434
7.94% 7.9% Direct
Antigen 53%** 96%**
$12
Meds $1.09
The use of a low-cost 
direct antigen test, more 
effective than not 
testing and or treating
Trachtenberg, 
et al.
(1988)
California
1986
F.P. clinics 
400,000 
annually
(as low as 
1.84% to 
2.59%) 
Baseline
5.98%
9.8% Micro­
Trak 90%** 98%**
$6.75 test 
$2 - meds 
$16- return visit 
$20 -visit & tx 
for partner
Universal screening cost 
effective if prevalence 
>6%
22 (table 3 continued)
Table 3. (continued)
Chlamydia: Cost Versus Benefit Studies
Location 
Date 
Type clinic 
Number 
screened
Break - 
even 
prevalence 
rate
Rate
Pos
Test
used
Sen Spec Cost of test 
&
Treatment
Conclusions
Humphreys, 
et al.
(1991)
Colorado
1988
F.P. clinics 
11,793
2% 7.7% Chlamy­
diazyme
EIA 79%** 97%**
Not screening
$0.00
Selective
Screening
$82,500.00
Universal
Screening
$203,500
Universal screening 
would decrease 
morbidity for clients 
with chlamydia & 
significantly reduce 
health care cost
Marrazzo
(1994)
Region X 
1990
F.P. clinic 
11,141
1.8% 
1.9% to 
3.5%
6.6% DFA
LCR
75%**
95%**
*97% 
to 99%
$5
$10-$25
Require 56% be tested 
78% detected. 
Selective screening is 
cost effective in low 
prevalence populations
Note Pos = positive Sen = sensitivity Spec = specificity DFA = direct fluorescent antibody EIA = enzyme immunoassay 
LCR = ligase chain reaction
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The cost of the direct antigen test was $ 12, and the cost of the medication was $ 1.09.
The authors concluded that the use of a low cost direct antigen test was more effective 
than not testing or treating clients for chlamydia.
California's state-hmded family planning clinics, with a reported prevalence rate of 
9.8%, were studied in 1986 using a decision tree. The purpose was to determine the total 
cost of universally screening or not screening the estimated 400,000 women, annually seen 
in California's state family planning clinics. The total cost of universal screening was 
$7,307,717 (Table 4). They compared this with the cost of $20,347,401 required to pay 
for hospitalization, surgical procedures, and medications for treatment of PID, ectopic 
pregnancies, infertility, and neonatal pneumonia and conjunctivitis, when no chlamydia 
screening was done. Break-even prevalence rates were determined to be as low as 1.84% 
to 2.59% using the MicroTrak nonculture test, with a sensitivity of 90% and specificity of 
98%. The MicroTrak test cost $6.75, medication per person was $2, the cost of a return 
client visit was estimated to be $16, and the cost of a contact partner visit and treatment 
was $20. As a result, universal screening was determined to be cost efifective if the 
prevalence rate was greater than 6% (Trachtenberg, Washington, & Halldorson, 1988).
A 1988 study conducted in 22 Colorado family planning clinics found that of 11,793 
females tested 913 tested positive, which calculated the prevalence rate to be 7.7%. The 
total cost of not screening for chlamydia in this study was $0 for direct cost and 
$1,370,000 for the indirect cost (Table 5). Indirect cost included outpatient and inpatient 
treatment related to PID, ectopic pregnancy, tubal infertility, epididymitis, and neonatal 
pneumonia and conjimctivitis. Although the selective screening criteria were not specified,
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Table 4.
Chlamydia Testing and Treatment: Cost Under Each Decision OotioiLat California Fanulv 
Planning Clinics
Screened ($) Unscreened ($)
Testing $2,700,000 $0
Treatment 1,529,856 0
Complications 127,488 0
Women with PID
Outpatient Rx 255,780 1,764,000
Hospitalization 1,270,928 8,765,022
Surgery 255,780 1,764,000
Epididymitis, outpatient 11,368 78,400
Epididymitis, inpatient 40,947 282,391
Ectopic pregnancy 327,342 2,257,528
Tubal infertility 746,025 5,145,000
In births to infected women;
Neonatal pneumonia 39,078 269,500
Neonatal conjunctivitis 3,126 21,560
TOTAL COSTS (1986 Dollars) $7,307,717 $20,347,401
Source: Trachtenberg et al. (1988). A cost-based decision analysis for chlamydia screening 
in California family planning clinics. Obstetrics and Gvnecologv. 71.104.
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Table 5.
Cost Decision Analysis for Chlamydia trachomatis Screening in Colorado Family Planning
Clinks.
Scenario
Screening Cost 
Dollars 
(Direct Cost)
Total Health 
Cost Dollar 
(Indirect Cost)
Total Cost 
Per 
Protocol
No Chlamydia Screening $0 $1,370,000 $1,370,000
Selective Screening $82,500 $1,120,000 $1,202,500
Universal Screening $203,500 $607,000 $810,500
Source: Humphreys et al. (1991). Cost-benefit analysis of selective screening criteria for 
Chlcanydia trachomatis in women attending Colorado family planning clinics. Sexually 
Transmitted Diseases. 19. 51.
the direct cost was $82,500, the indirect cost of selective screening was $1,120,00 for a 
total cost of $1,202,500. This figure was based on the a) cost of testing using the 
Chlamydiazyme EIA nonculture test with a sensitivity of 79% and a specificity of 97%, 
b) treatment as needed for those selectively screened, and c) the cost of treating 
complications in clients not screened who were subsequently found to have chlamydia. 
Universal screening was estimated at $203,500 for direct cost and $607,000 for indirect 
cost, with a total of only $810,500. This low cost was attributed to the cost of routine 
testing and early treatment of chlamydia, which eliminated or reduced the occurrence and 
cost of treating complications. This study was based on the application of the
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Trachtenberg decision model, used in California in 1986, to determine the total cost of 
screening versus the cost of not screening, using a break-even point of a 2% prevalence 
rate. Although state and federal funds only support selective screening at this time, 
Humphreys, Hennebeny, Rickard, and Beebe (1991) noted that universal screening would 
decrease the morbidity for clients with chlamydia and significantly reduce health care cost.
Region X conducted a study in 1990. Their 6mily planning clinics, located in 
Washington, Oregon, Alaska, and Idaho, selectively screened 11,141 females. Seven 
hundred-thirty-five subjects tested positive, for a prevalence of 6.6%. They found that 
selective screening would require testing 56% of the &mily planning clients, and that 78% 
of chlamydia infections would be detected. Cost effectiveness was based on the prevalence 
of chlamydia in the target population, the sensitivity of the screening criteria, the 
sensitivity of the diagnostic test, and the cost of the diagnostic test used. It was 
determined that, in a predominantly asymptomatic family planning population, selective 
screening is cost-effective if the prevalence rate is low. T h ^  defined low in this study to 
be less than 1.8%, using the DFA which had a sensitivity of 75% and cost $5 per test. 
However, 1.9% to 3.5% was the breaking point when the ligase chain reaction (LCR) test 
was used, which had a sensitivity of 95% and cost $10 to $25 (Marrazzo, 1994).
Cost versus benefit analysis were affected by the prevalence rates of each individual 
study, when compared to the direct and indirect cost of testing and treatment. The 
prevalence rates were influenced by the sensitivity and specificity of the nonculture test, 
which was most widely used for screening high risk clinic populations. In spite of these
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diflferences, studies showed that the break-even prevalence point still averaged 6% to 8% 
in high risk populations.
Theoretical Framework
Betty Neuman's Systems Theory provided the conceptual framework for this study. 
Her concept of secondary prevention as intervention relates to the early detection and 
treatment of physiological health problems. Her concept of health is the maintenance of a 
stable state. Neuman's client system model (1989) (Figure 1) represents a wholistic view 
of the client. This system's core is conceptualized as being protected by three sets of 
concentric rings. The core represents basic survival factors that relate to genetic response 
patterns, ego structure, cognitive ability, along with the strengths and weaknesses of body 
organs. The concentric rings consist of the flexible line of defense, the normal line of 
defense, and the lines of resistance. A dynamic flexible line of defense represents the outer 
concentric ring. The more distance between the flexible line of defense and the normal line 
of defense, the greater buffer it provides for the client's normal or stable state of 
health. The flexible line of defense constitutes the individual's immediate response to 
stressors. The normal line of defense is the next level of protection in Neuman's client 
system model. It lies between the flexible line of defense and the lines of resistance and 
represents the client's ability to maintain a dynamic equilibrium. It includes those resources 
for adapting to internal and external stressors that have been developed over a lifetime. 
Neuman (1995) states, " . . .  when the normal line of defense has been penetrated, the 
client presents with symptoms of instability or illness, caused by one or more impacting
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1) Flexible Line of Defense 
Le. *) Knowledge related to 
prevention of STD’s
b) Use of Condoms
\ \
Basic
Stnctnre
w
\ \
2) Normal Line of Defense 
Le. Famii^ Vabes 
a) abstinence
3) Lines o f Resistance
Le. a) Level of physical psychological.
b) monogamous relationslup developmental, sociocnltiiral & 
spiritual weHncss 
b) Compliance with prescribed 
treatment
Figure 1. Neuman's client system model.
Source: Neuman, B. (1995). Systems and nursing: Conceptualization of the Neuman 
Systems Model. The Neuman Systems Model (3rd ed.) ( p.28), Norwalk, CT: Appleton & 
Lange. Adapted with permission.
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stressors " (p. 27). Protecting the core is the innermost concentric ring, called the lines of 
resistance. When stressors invade the normal line of defense, the lines of resistance are 
involuntarily activated in an attempt to stabilize the client's system by restoring its normal 
line of defense.
Neuman’s (1995) concept of stressors includes intrapersonal, interpersonal, and 
extrapersonal sources. Each source includes physiological, psychological, developmental, 
sociocultural, and spiritual variables. Betty Neuman further focused on her concepts of 
primary, secondary, and tertiary prevention as interventions and on reconstitution (Reed,
1993). Intrapersonal stressors relate to the client's physical functioning. For example, the 
immaturity of the adolescent and young adult female's reproductive tract makes her more 
susceptible to contracting a chlamydial infection (Touchstone & Davis, 1992). Also the 
use of drugs and/or alcohol reduces inhibitions that consequently may increase the 
incidence of multiple partners and decrease the likelihood of barrier protection being used. 
Interpersonal stressors relate to the client's interaction with her external environment. For 
example, having multiple partners or having a partner with multiple partners increases the 
likelihood of being exposed to chlamydia. Extrapersonal stressors are also part of the 
client's external environment but are more abstractly related, such as a lack of education 
related to the transmission of chlamydia, and the media hype which portrays promiscuous 
sexual encounters to be desirable. For example, a client's flexible line of defense may be 
her knowledge related to the prevention of STD's or her use of condoms. Her normal line 
of defense may be her Amily values (abstinence or a monogamous relationship) and the 
environment in which she lives (a community that provides easy access to routine health
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care). Her lines of resistance may be the maintenance of a high degree of physical, 
psychological, sociocultural, developmental, and spiritual wellness, and the compliance 
with treatment of sexually transmitted diseases when needed (Neuman, 1995).
Neuman's Systems Theory states that once the client's normal line of defense is 
broken, instability (infection) occurs. The primary concern of health care professionals is 
prevention. Therefore, Neuman's primary prevention as intervention is of prime interest. 
The purpose of primary prevention as intervention is to promote client wellness by 
prevention of stress and the reduction of risk factors (Neuman, 1995) (Figure 2). The first 
goal is to encourage the client to protect her normal line of defense by "...a) increasing her 
flexible line of defense's ability to withstand environmental stressors", for example, the use 
of condoms for protection; and by "b) decreasing risk factors" (Reed, 1993, p. 14), by 
remaining abstinent, maintaining a mutually monogamous relationship, or by decreasing 
her number of partners. Primary prevention interventions include providing risk reduction 
education and counseling and making condoms readily available.
When primary interventions are not utilized or are ineffective, secondary prevention as 
intervention must be mobilized (Figure 3). Early, secondary prevention as intervention 
prevents more severe illnesses fi’om occurring (CDC, 1993). In this study, secondary 
prevention as intervention refers to selective screening or early testing for chlamydia and 
providing early treatment when needed. Early treatment allows clients to return to a 
stable state as soon as possible thus preventing the long term consequences of an 
unidentified, untreated chlamydial infection (Neuman, 1995).
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1) Stxestor: 
i.e. Cblamydût
2) AiSMiment of Streicor to antictpate 
poiiiblfi coaaeqnancet of potential 
iUneai;
i.e. Univenal Screening
for Chlamydia /
I
3) Intervention to preveitt invaaion of atreaaor 
Le. Reinforce need for coneietent 
nae of condom#
4) Goal: To atrengthen flexible line-defenae: 
Le. Client uaea condoma as a 
prevention measure
Figure 2. Format for primary prevention as intervention model.
Source; Neuman, B. (1995). Systems and nursing: Conceptualization of the Neuman 
Systems Model. The Neuman Svstems Model (3rd ed.) (p.34), Norwalk, CT: Appleton & 
Lange. Copyright 1980 by Betty Neuman. Adapted with permission.
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StRHor:
Le. Chlamydia 4} Qoal: To protect Boiie Structure
and facilitate WeOneaa/ 
Recomatniction 
Le.Tieatmeat effective 
in curing chlamydia
1) Reaction to atreeaora:
Le. Preaenec of mucopurulent 
diacharge
w
Basic
Structure
2) Asaeaament of the degree of 
reaction to atreaaora to facilitate 
treatment/hiterventioa:
Le. Selectivea acreening for 
chlamydia 3) hrtervention to reduce degree of
reaction to atreaaora:
Le. Treat forpoaitve chlamydia
Figure 3. Format for secondary prevention as intervention model.
Source: Neuman, B. (1995). Systems and nursing: Conceptualization of the Neuman 
Systems Model. The Neuman Svstems Model (3rd ed.) (p.35), Norwalk, CT: ^ p le to n  & 
Lange. Copyright 1980 by Betty Neuman. Adapted with permission.
33
The final phases of Neuman's Systems Theory are reconstitution and tertiary 
prevention as intervention. Once the client is successfully treated for the chlamydial 
infection, tertiary intervention is needed for reconstitution to be maintained Education and 
counseling focused on compliance with prescribed treatment and prevention of future 
infection were examples of tertiary prevention in this study, and reconstitution was the 
return of the client's system to its pre-infectious state of well-being.
SmnmaiY.
This literature review, which included universal screening, selective screening, and 
cost benefit analysis studies, pointed to the cost effectiveness of selective screening in low 
prevalence populations, when nonculture test were used. Selective screening, however, 
was not found to be cost efifective in high prevalence populations. According to the CDC 
(1993), the Gen-Probe nonculture test has a comparable sensitivity to the DFA and EIA 
nonculture test. In a 1989 article. Dr. Russell Phillips stated "In any patient population 
where the prevalence of chlamydial infection is greater than 7%, routine (universal) 
screening of all patients would be cost efifective" (p.93). The Centers for Disease Control 
states that "... a prevalence of <5% is considered to be low prevalence" ( p. 17), and that 
"High = >5%" (p. 14). Although CDC acknowledged that the 5% prevalence rate is 
arbitrary, it is based on the use of nonculture tests such as Chlamydiazyme EIA, and 
MicroTrak DFA, which all have approximate specificities of 99% and sensitivities of 80%. 
Because universal screening was recommended for use in high risk populations, CDC's 5% 
guideline was used in this study to determine whether these family planning clinics should 
be designated as low or high risk populations.
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According to the Prevention Centers of Disease Control in Atlanta (ffiUis et al., 1995), 
unlike viral infections such as HTV, herpes, and genital warts; bacterial infections, 
including gonorrhea and chlamydia, can be cured. It was pointed out that in Sweden, PID 
has heen nearly eradicated due to collaborative ^ o rts  among health care providers, policy 
makers, educators, the media, as well as other related parties. If the Healthy People 2000 
objective to reduce the spread of STD's in the United States is to be met, federal, state and 
local authorities must allocate funds to provide widespread screening and treatment of 
chlamydia. Researchers believed that the cost of treating PID and infertility, which are the 
primary complications of chlamydia, far outweigh the cost of universally screening low 
risk clients in high risk populations (Sellors et al., 1992).
Pgfioition of Tsnpg
High Prevalence Population - A population with a chlamydia prevalence rate equal to 
or greater than five percent ^5% ).
High Risk Group - Clients who have one or more risk factors, as assessed by the 
Chlamydia Risk Assessment Tool, using the MDCH guidelines.
Low Risk Population: A population with a chlamydia prevalence rate that is less than 
five percent (<5%).
Low Risk Group - Clients who do not have any risk fectors, as assessed by the 
Chlamydia Risk Assessment Instrument, using the MDCH guidelines.
P- Value - The probability that the results obtained are not due to chance alone.
Prevalence Rate: - The number of identified cases of chlamydia divided by the total 
sample population after the study period of seven consecutive months.
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Risk Factor - A single characteristic statistically associated with, although not 
necessarily causally related to, an increased risk of contracting chlamydia.
Screening - The collection and laboratory testing of endocervical epithelial cell tissue 
specimens for the presence of Chlamydia trachomatis, using a Gen-Probe collection kit.
Selective Screening - The testing of clients who have one or more risk factors for 
chlamydia as defined by MDCITs selective screening protocol. The risk factors were 
a) having more than one sex partner in the past 6 months, b) having a new sex partner in 
the past 6 months, c) having a history of an STD in the past 6 months, d) having a 
discharge or mucopurulent cervicitis, or e) having a fiiable cervbc.
Selective Screening Prevalence Rate - The number of identified cases of chlamydia, 
using MDCITs selective screening protocol, divided by the total sample population at a 
specific time.
Universal Screening - The testing of all clients for Chlamydia trachomatis who were 
seen in one of three health department family planning clinics for an annual or initial 
examinations.
Universal Screening Prevalence Rate - The number of identified chlamydia cases, using 
universal screening protocol, divided by the total sample population after the study period 
of seven consecutive months.
Research Questions
1. What is the prevalence rates of chlamydia in the low risk young adult females seen in 
this health department’s family planning clinics?
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2. What is the prevalence rates of chlamydia in the high risk young adult females seen in 
this health department’s family planning clinics?
3. Is there a significant difference in the prevalence rates between young adult females 
who were considered low risk and those who were considered high risk for chlamydia?
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CHAPTERS
METHODOLOGY
Rgseargh Design
This study used a descriptive two group comparison ex post facto/coneXaûon design 
and a convenience sample to examine the risk for chlamydia. The independent variable was 
the risk category as determined by the Chlamydia Risk Assessment Instrument. The 
dependent variable was the outcome of the chlamydia test. Each client was given a self- 
report questiormaire that assessed her risk category for the chlamydial infection. The 
questionnaire was reviewed by the nurse during the client’s routine pre-exam assessment 
interview. The clinician documented on the questionnaire the presence or absence of high 
risk factors observed during the physical examination. An independent laboratory 
determined the results of the nonculture chlamydia test.
Human Subjects
Approval for the ex-post facto portion of this study, which involved the review, 
assessment, and analysis of related client records, was also given by Grand Valley State 
University's Human Research Review Committee (Appendix A). To maintain client 
confidentiality, the client's clinic identification number was deleted fi'om the questiormaire 
after the result were recorded and reviewed for completeness by the researcher. A 
sequential record number was then assigned. When the clinic visit was completed, the risk
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assessment information was used for statistical purposes only and did not become a part of 
the client's chart. All information was handled confidentially by the health department staff. 
All reasonable efforts were made to maintain client confidentiality and to maintain an 
unbiased, accurate collection and analysis of the data.
Instm.msat
A chlamydia risk assessment instrument (Appendbc B) was developed by the author as 
a questionnaire to collect general, demographic, and risk assessment data for each client. 
General information included the clinic location, client identification number, type of visit, 
and payment category. Demographic data, necessary to accurately describe the 
characteristics of the sample population, included age, race, educational level, and marital 
status. To assess the client's risk category, questions relating to new partners, multiple 
partners, recent gonorrheal infections, presence or absence of genital discharge, and 
presence or absence of a friable or mucopurulent cervix, were included. To assess other 
possible risks, questions related to the presence of urinary tract symptoms, abdominal or 
pelvic pain, and the use of antibiotics or vaginal products were asked.
CQDlSDl_yalidily and Reliability
The content validity and reliability of this instrument was based on the Act that the 
general, demographic and risk factors questions were all previously tested. Another 
contributing Actor was the limited number of people involved in specimen collection and 
data analysis. The general and demographic information was the same information 
collected by the health department for all client visits. Seven of the risk factors assessed, 
relating to partners and clinical findings, were the same factors used by the Michigan 
Department of Community Health for selective screening purposes. Additional questions
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relating to pain and the use of condoms were taken from other selective screening studies 
as possible high risk factors. The question, relating to the use of antibiotics and vaginal 
preparations was also taken from other studies and used to determine possible causes of 
negative results. This questionnaire and those used in other studies were limited by the 
information shared with us by the clients and by the estimation that 50% to 80% of clients 
with chlamydia are asymptomatic.
Several colleagues with experience developing questionnaires reviewed the instrument. 
It was pilot tested during two family planning clinic sessions at one clinic site. 
Modifications made were to have clients specify age, rather than select from an age group 
and to specify a co-pay category, rather than select from a co-pay range group.
There was only one nurse practitioner and one physician collecting specimens in this 
study, and the nurse practitioner was the only researcher involved in the study. Both the 
nurse practitioner and the physician were trained in the proper technique for specimen 
collection, according to the Gen-Probe manufecturer instructions. The results were 
determined by an independent laboratory.
Study Site and Subjects
In 1996, the health department conducted a study that assessed the risk factors of their 
family planning clinic populations, to reevaluate their current selective screening protocol 
for chlamydia. Two of their urban clinics (having the highest prevalence rates from 1992-
1994) and one rural clinic (prevalence rate unknown) were chosen for this study. Four 
hundred and three female subjects were screened for chlamydia. All were clients between 
20 to 39 years of age who were seen for an initial or aimual examination, during the seven 
consecutive months of this study. The Michigan Department of Community Health
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supported this study by making the chlamydia nonculture specimen collection kits (Gen- 
Probe) available to the health department at a reduced cost and assumed the cost of the 
laboratory testing.
Procedure
When the client came into the clinic for her scheduled initial or annual family planning 
examination, she was given a self-report questionnaire to complete along with other clinic 
forms. A clinic nurse reviewed the questionnaire with each client during her routine 
pre-exam assessment interview. Explanations and/or clarifications were provided by the 
nurse as needed. Each client was then seen by a nurse practitioner or physician, and a 
endocervical specimen was taken during a routine pelvic examination. A Gen-Probe 
specimen collection kit, containing two Dacron swabs with diluent, was used to collect 
each specimen. The chlamydia specimen was taken before other specimens such as the Pap 
smear or gonorrhea culture. Excess cervical mucous was removed with the first swab and 
discarded. The second swab was used to collect the chlamydia specimen. To insure the 
collection of sufficient endocervical cells necessary for an accurate test, the Dacron swab 
was placed into the cervical os and rotated for 30 seconds. Gen-Probe has a sensitivity of 
90% and a specificity of 100% (Miettinen, Vuorinen, Varis, & Hallstrom, 1995). After 
placing the second swab into the collection bottle with the diluent, the top of the swab was 
broken off near the top of the container and the cap screwed on tightly. The specimen was 
labeled with the client’s name, identification number, and date. After completing each 
examination, the clinician recorded the presence or absence of a fiiable or mucopurulent 
cervix on the bottom of each survey. The specimen was mailed to the processing
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laboratory at the end of that clinic day. V^thin five to seven working days the laboratory 
mailed the results back to the clinic and the results were recorded on the questionnaire.
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CHAPTER 4 
DATA ANALYSIS
This study compared the chlamydia prevalence rates of the low and high risk groups, 
within a health department's Amily planning clinic, using the Gen-Probe nonculture test. 
The purpose of this study was to detennine a) the prevalence rates of chlamydia in 
designated low risk groups, b) the prevalence rates of chlamydia in designated high risk 
groups, and c) if there was a significant difference between the prevalence rates of these 
two groups.
Sample Characteristics
The sample consisted o f403 adult females, aged 20 to 39, seen in one of three family 
planning clinics within a local health department. During a period of seven consecutive 
months, all nonpregnant clients who were seen in these clinics for annual exam (60.8%) or 
an initial examination (39.2%), were included in this study (Table 6). All of the clinics 
were located outside a metropolis. Sites A and C were urban clinics having 47 and 297 
participants respectively, and Site B was a rural clinic with 59 participants. Family incomes 
were as follows a) 80.9% had incomes of <100% of the poverty level, which qualified 
them for no cost family planning services, as identified by a 0% co-pay; b) 18.1% had 
incomes of 100% to < 175% of poverty and were billed 20% to 60% of the total visit 
cost, and c) 1% had incomes >175% of poverty and were billed 80% to 100% of the clinic
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Table 6.
Type Visits and Percentage of Co-Pav for Each Clinic
Site A 
11.7% 
(n = 47)
SiteB 
14.6% 
(n = 59)
SheC 
73.7% 
(n = 297)
All Sites 
100% 
(N = 403)
Type Visits
Initial 38.0% 57.6% 35.7% 39.2%
Annual 61.0% 42.4% 64.3% 60.8%
% of Co-Pay
0% 91.5% 76.3% 80.1% 80.9%
20%- 60% 8.5% . 22.1% 18.8% 18.1%
80%-100% 0% 1.7% 1.0% 1.0%
cost. All fees and co-pays were assessed on the date of their clinic visit using the 1996 
WCHD/ Federal guidelines (Department of Health & Human Services, 1996). Forty-five 
percent of the total sample were between the ages of 20 and 24 years of age and 54.8% 
were 25 years and older (Table 7). The mean age was 25.97, with a standard deviation of 
4.7. The racial makeup consisted of 65.5% White, 31.0% Black, and 3.5% other. Of all 
the subjects in this study, 13.3% of them had not completed high school, 36.1% were high 
school graduates, 43.9% had completed some college credits, and 6.8 % were college 
graduates. The largest percentage of the sample were single, not living with their partner 
(49.9%). The rest of the sample were more evenly distributed with 19.2% single, living 
with partner, 16.2% married; and 14.6% were separated, divorced or widowed.
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Table 7.
Comparison of Demographic Data Prevalence Across Sites
Site A SiteB SiteC All Sites
Clients 11.7% 14.6% 73.7% 100%
Age
20 - 24 years 45.2% 44.1% 46.5% 45.2%
> 25 years 54.8% 55.9% 53.5% 54.8%
Race
Black 91.5% 13.6% 24.9% 31.0%
White 8.5% 83.0% 71.0% 65.5%
Other 0% 3.4% 4.1% 3.5%
Education
<I 1th grade 0% 22.0% 13.6% 13.3%
High school grad 25.5% 40.4% 36.9% 36.1%
Some college 66.0% 33.3% 42.4% 43.9%
College graduate 8.5% 3.5% 7.1% 6.8%
Marital status
Single not living 
with partner
68.1% 42.4% 48.5% 49.9%
Single living 
with partner
14.9% 16.9% 20.3% 19.2%
Married 6.4% 25.4% 15.9% 16.2%
Sep/Div/Wid 10.6% 15.3% 15.2% 14.6%
Demographically Sites B and C were quite similar. Seventy-one percent to 83% were 
White, 42.4% to 48.5% of the clients were single and not living with their partner, and 
33.3% to 42.4% had some college education. Also noted was that 76.3% to 80.1% had a
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0% co-pay. Site A identified a much higher percentage of Black participants (91.5%), a 
slightly higher percentage of 0% co-pays (91.5%), with 68.1% of the clients identified as 
single and not living with their partners. In addition. Site A had a higher percentage of 
subjects with some college (66.0%) and a slightly higher percentage of college graduates 
(8.5%) than Site C. Site C was shown to have 7.1% college graduates, according to the 
self-report questionnaire, and Site B reported the lowest percentage (3.5%) of college 
graduates.
Risk Factor Results
Although having sex without using a condom is not one of MDCITs criteria for 
selective screening, failure to use condoms was assessed as a possible risk factor for 
chlamydia. Of the 403 subjects screened, the mean prevalence for those who had sex 
without using condoms, sometime in the last six months, was 72.3% (290).
Seven risk factors were used to differentiate the high risk groups fi*om the low risk 
groups (v^pendix C). The most frequent MDCH selective screening risk factor, identified 
in this health department, was having a new parmer (20.6%) in the past six months. The 
prevalence of risk factors among those clients who tested positive for chlamydia were as 
follows a) having a new partner in the past sbc months (45.5%) (Appendix D); b) having 
more than one partner in the past six months (25.0%); c) having a friable cervix on 
examination (16.7%); d) the client or her partner having an unusual discharge (16.7%);
e) having a partner who has had more than one partner in the past six months (9.1%);
f) having a mucopurulent cervical discharge on examination (8.3%); and g) the client or 
her partner having had gonorrhea in the past six months (8.3%). If none of the previous
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risk factors were identified, the client was designated as low risk. If any of the previous 
risk factors were identified the client was designated as high risk. If there were no 
response checked (yes or no) on any one of the risk Actor questions, and no other high 
risk factor was indicated, the case was counted as missing.
Chlamydia Prevalgnçg Ratgs
The prevalence rates for chlamydia in the low risk groups were Site A, 6.4%, Site B, 
0%, Site C, 0.3%, and the mean low risk prevalence rate was 1.0% (Table 8). The mean 
high risk group prevalence rate was 1.8%. Site A's high risk group prevalence rate was 
6.4%; Site B 1.8%, and Site C was 1.0%. The total chlamydia prevalence rates of each 
clinic (Table 9), which included both the low risk and the high risk groups, were Site A, 
12.8%, Site B, 1.7%, Site C, 1.7%, and the mean rate was 3.0%.
A chi-square test with Yates correction was used to compare the test outcome with 
the risk designator. There was no significant difference in the diagnosis of a chlamydial 
infection, between the clients who were designated as low or as high risk, in any of the 
clinics or in the combined population. (Chi Square =1.8, df = 1, p = . 18). The total clinic 
prevalence rates in Site B of 1.7% and Site C of 1.7% were well below the 5% prevalence 
rate that CDC uses as a guideline to determine the low risk from the high risk groups.
Site A however, whose prevalence rate was 12.8%, was well above 5%. Also their low 
risk group's prevalence rate (6.4%) was equal to that of their high risk group's prevalence 
rate (6.4%). According to Dr. Phillips (1989), as well as multiple other universal and 
selective screening studies. Sites B and C fit into the selective screening category based on 
their low prevalence rates, even though there was no significant difference between their
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Table 8.
Chlamydia;. UiûYsrsal Sçrggnins Results
Low Risk 
Positive
High Risk 
Positive
Low Risk 
Negative
High Risk 
Negative
Totals
Site A 6.4% 6.4% 46.8% 40.4% 100%
(3) (3) (22) (19) (47)
SiteB 0% 1.8% 56.1% 42.1% 100%
(0) (1) (32) (24) (57)
Site C 0.3% 1.0% 62.0% 36.7% 100%
(1) (3) (183) (108) (297)
Combined 1.0% 1.8% 59.4% 37.8% 100%
Sites (4) (7) (237) (151) (399)
Note. Nfissinecases: SiteB (2 )negatives
Site C (1) negative & (1) positive
Table 9.
Universal Screening Prevalence Rates
Total Participants Total Positives Prevalence Rates
Site A 47 6 12.8%
SiteB 59 1 1.7%
SiteC 297 5 1.7%
Combined Sites 403 12 3.0%
low risk and high risk groups. Site A, however, fits into the universal screening category 
based on their prevalence rate of 12.8% being well above 5%, and because there was no 
significant difference between their low risk and their high risk groups.
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OthsT-findings
Additional questions were added to assess other possible high risk factors for those 
testing positive for chlamydia. Included were clients who had a) sexual intercourse at 
anytime in the past six months without using condoms (91.7%); b) used antibiotics, 
vaginal medications, or douched in the past 48 hours (18.2%); c) lower abdominal or 
pelvic pain at the time of examination (8.3%); or d) pain, burning, or frequency of 
urination (0%).
In order to determine if a lack of knowledge relating to their partners history had an 
influence on the subjects ability to accurately respond to some of the questions on the risk 
assessment form, a "dont know" category was added to two of the questions. The first 
question asked was had their "partner had more than one partner in the last six months?" 
A third (36.4%) of the participants answered "dont know". The second question asked 
was had their "partner had a positive test for gonorrhea in the past six months?" A 
smaller percentage (16.7%) of those responding indicated that they didnt know.
There were no significant differences in the other chlamydia prevalence rates or in the 
risk factors used to predict the risk for the low and high risk groups. One point of focus 
was that 72% of the total client sample population reported having had sexual intercourse 
without using condoms at least once within the last sbc months, but only 35.4% reported 
being married or living with their partner. Eleven (91.6%) of those testing positive 
admitted to having sex without a condom at sometime during the past sbc months, but one 
subject denied doing so. This supports the belief that chlamydia can persist for up to 15 
months as stated in the Primary Care Update (1994).
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When looking at other factors, all clients with a positive test were in the 0% co-pay 
category, indicating that they reported an income below poverty level. Seventy-five 
percent were single, and none were college graduates. Although there was a total of 403 
participants in this study, the total number of subjects with a positive test for chlamydia 
(12) was too low to adequately test the risk assessment screening criteria.
50
CHAPTERS
DISCUSSION
Smrniary and CgoslysioQ
Adult females (N=403) from three clinical sites were universally screened for 
chlamydia risk factors, using a self-report chlamydia risk assessment form. Clients were 
accustomed to filling out the HIV risk assessment questionnaire, as part of the health 
departments routine interviewing process. This may have contributed to their 
cooperativeness in completing this chlamydia risk assessment instrument. The risk 
assessment tool also provided the nurses with a more structured format in which to 
discuss this, often silent, STD.
Based on the client's responses on the questionnaire, she was placed in either a low 
risk or a high risk group and tested to determine if a chlamydial infection was present. 
Twelve (3.0%) subjects tested positive. The primary purpose of this study was to 
determine if the use of the risk assessment tool to classify clients as low or high risk would 
accurately predict the results of a test for Chlamydia trachomatis. The secondary purpose 
was to determine the chlamydia prevalence rate at each clinic. Each clinic was then 
categorized as a low or high risk population, using CDC's S% guideline. After analyzing 
the results, 241 (60.4%) were classified as low risk while 158 (39.6%) were placed in the 
high risk category with four missing cases. Four (1.0%) of the 12 subjects with chlamydia
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were in the low risk group and seven (1.8%) were in the high risk group with one missing 
case.
The conclusion was that the mean prevalence rate of the health department's family 
clinics was 3% which categorized it as a low risk population. Sites B and C both had 
prevalence rates of 1.8% each, which is consistent with the mean rate categorization.
Site A, however, had a prevalence rate of 12.8%. Having a rate > 5% places Site A in the 
high risk category, and should, therefore, be evaluated independent of Sites B and C.
Having less than a ninth grade education was reported by Holmes et al. (1993), to be a 
risk factor for chlamydia; however, Addiss et al. (1987) stated there is no relationship 
between a positive chlamydial infection and education. In addition, none of the other 
studies, documented in this literature review, assessed this relationship. In this study.
Site A with a prevalence of 12.8%, reported the highest rate of clients with college 
degrees or with some college education (74.5%). This was compared to 49.5% at Site C 
and 36.8% at Site B, even with almost identical mean ages.
Also of interest are the findings related to race. In the literature review Handsfield 
et al. (1986), Addiss et al. (1987), and Han et al. (1993) reported no relationship existed 
between race and a chlamydial infection. Only CDC (1994) reported the presence of a 
relationship. Although five of the sbc clients with a positive test in Site A were Black, the 
prevalence was only 11.6%, while the prevalence for Whites was 25%. The greater 
number (5 out of 6) was most likely related to the fact that 91.5% of the clients at Site A 
were Black.
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Another point of interest was the relationship between low income and the presence of 
chlamydia. Although it was not discussed in the literature reviews, it was noted that all the 
clients with a positive chlamydia test in this study, and 91.5% of Site A's total sample 
group reported incomes below the poverty level. Again, because there were only 12 cases 
of chlamydia identified in this study, no determination of differences in physical or 
socioeconomic risk factors could be made between those with or without chlamydia or 
among the three sites.
Taking a closer look at the clients at Site A who had chlamydia, compared to those 
who did not have chlamydia, the following data was noted for demographic variable 
categories (Table 10). Of those with chlamydia, 66.7% were age 24 or younger, while 
only 34% of those without chlamydia were in this age bracket. Thirty-three percent of 
clients with chlamydia were single and living with a partner. None were married or 
divorced. Of those without chlamydia, 12% were single and living with a partner, while a 
similar percentage were divorced, separated or widowed, and 7% were married. White 
clients comprised 16.7% of those with chlamydia and 7.3% of those without chlamydia. 
There was approximately the same percentage of clients with chlamydia as those without 
who were Black, high school graduates, or with some college education, and those who 
were single and not living with their partner. The most prominent social risk factor was 
having sex without using a condom (83.3% vs 53.7%), as compared to those who did not 
have chlamydia (Table 11). Other risk factors were a) having multiple partners (33.3% vs 
17.1%), b) having a partner with multiple partners (16.7% vs 9.8%), c) having a new 
sexual partner (33.3% vs 22%), and d) having an unusual discharge (33.3% vs 22%).
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Table 10.
Site A Client Demographics: With and Without Chlamvdia
With Chlamydia 
n = 6
Without Chlanqrdia 
n = 4I
Total Site A 
n = 47
AGE 20 - 24 years 66.7% (4) 34.1% (14) 38.3% (18)
>25 years 33.3% (2) 65.9% (27) 61.7(29)
RACE Black 83.3% (5) 92.7% (38) 91.5% (43)
White 16.7% (I) 7.3% (3) 8.5% (4)
EDUCATION
High school graduate 33.3% (2) 24.4% (10) 25.5% (12)
Some college 66.7% (4) 65.9% (27) 66.0% (31)
College graduate (0) 9.8% (4) 8.5% (4)
MARITAL STATUS
Single not living 
with partner 66.7% (4) 68.3% (28) 68.1% (32)
Single living 
with partner 33.3% (2) 12.2% (5) 14.9% (7)
Married (0) 7.3% (3) 6.4% (3)
Sep/Div/Wid (0) 12.2% (5) 10.6% (5)
Limitations and Recommendations
The fact that only 12 subjects tested positive was a major limitation of this study. The 
number of subjects with chlamydia was too low to statistically test the risk assessment 
tool's ability to accurately predict test results. However, the fact that Site A had a 12.8% 
prevalence rate indicated that it should be considered a high risk population at this time.
54
Table 11.
Sits A  Client RiskJEagtprs: With and.Withoyt Chlamydia
With Chlamydia 
n = 6
Without Chlamydia 
n  = 41
Total Site A 
N = 47
New partner < 6 months 33.3% (2) 22.6% (9) 23.4% (11)
Multiple partners (n ç  ) 
< 6  months 33.3% (2) 17.1% (7) 19.1% (9)
Partner with n^) Yes 16.7% (1) 9.8% (4) 10.6% (5)
D on't know 33.3% (2) 22% (9) 23.4% (11)
Gonorrhea - self or partner 
tx < 6 months Yes 16.7% (1) 2.4% (1) 4.2% (2)
D on't know 16.7% (1) 12.2% (5) 12.8% (6)
Unusual discharge 33.3% (2) 22% (9) 23.4% (11)
Sex without condoms No 16.7% (1) 46.3% (19) 42.6% (20)
Yes 83.3% (5) 53.7% (22) 57.4% (27)
Pain, burning or hequency of 
urination (0) 7.3% (3) 6.4% (3)
Abdominal^elvic pain 16.7% (1) 24.4% (10) 23.4% (11)
Antibiotics, vaginal meds, or 
douching <48 hours 16.7% (1) 14.6% (6) 14.9% (7)
Mucopurulent cervicitis (MPC) 16.7% (1) 14.6% (6) 14.9% (7)
Friable cervix (0) 14.6% (6) 12.8% (6)
Both the prevalence rates of the high risk group in Site A (6.4%, 3) and the low risk group 
(6.4%, 3) were equal. This indicates that further study is needed to detennine if the 
assessment tool, based on the MDCH screening criteria, is adequate to determine who 
should or should not be screened. It was, therefore, recommended that universal screening 
be continued at Site A until that determination can be made. Although there was no
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significant difiference between the low risk and the high risk groups at Sites B or C in 
relation to the number of positive results obtained, their mean prevalence rates fell well 
below the 5% prevalence rate. Therefore, universal screening was terminated and selective 
screening protocols were resumed.
Because Site A is a high risk population (12.8%), as opposed to the low risk 
populations of Sites B and C (1.8% each), future study using the Health Belief Model was 
recommended to assess the beliefs, values, and attitudes of that population toward 
sexually transmitted diseases and the use of primary prevention measures. The Health 
Belief Model (HBM) assumes that the client must a) believe that her health is in jeopardy, 
b) perceive the potential seriousness of having complications related to an untreated 
chlamydial infection, c) believe that the benefits firom the recommended behavior outweigh 
the costs or inconvenience and are within her ability to do, and d) have a "cue to action" 
that makes her feel the need to use primary preventive measures (Green & Kreuter, 1991).
According to Simon and Das (1984), it is helpful to assess data on a group's 
perception of various aspects of the HBM prior to developing an educational program for 
a particular group, such as Site A  These authors recommended the use of the Venereal 
Disease (VD) Education Health Belief Model Scale Dimensions in analyzing similar 
populations. This model uses a 5-point scale ranging Grom strongly agree to strongly 
disagree to rate several questions in five major scale categories. These scales are the 
Susceptibility Scale, Seriousness Scale, Barrier Scale, Benefit Scale, and the Likelihood 
Scale (Appendk E). Examples of questions on these scales are a) Susceptibility Scale;
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I am too young to have venereal disease, b) Seriousness Scale: an attack of gonorrhea 
might make me unable to have children, c) Barrier Scale: I am too embarrassed to go for 
VD checkups, and d) Benefit and Likelihood Scale: telling my sexual partner(s) if I 
suspect that I have VD. Once this data has been collected and assessed, health 
professionals can tailor a program more suited to the specific needs of Site A's high risk 
population. Although this model by Simon and Das is an excellent model, it is 
recommended that it be updated to reflect the change in terminology fi'om the use of 
Venereal Disease (VD) to the current use of Sexually Transmitted Disease (STD). Also 
recommended is a change reflecting the current recommendation for yearly physical 
examinations, unless otherwise indicated.
Other limitations of this study included the use of convenience sampling, whereby 
clients were self-selected by coming to one of the three pre-selected clinics, pre-designed 
for use by low and no income clients. Due to the limited number of available participants, 
random sampling was not recommended.
Prior studies have shown that although there are many risk factors that may place a 
client in the high risk category for chlamydia, the only consistent demographic risk factor 
found is being less the 20 years of age (Wiesmeier et al., 1984; Handsfield et al., 1986; 
Addiss et al., 1987; Han et al., 1993, & CDC, 1994). Because there has been no single 
physical risk factor or group of risk factors identified as a positive predictor for this 
sexually transmitted disease, further studies are needed. One of the most frequent 
recommendations is for further development of less costly, less invasive, and more 
sensitive test that would make widespread universal screening practical. At the present
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time the development of a more sensitive rapid stat test would be beneficial. Due to the 
dffîculty encountered with cbent follow-up such as a) contacting clients in a confidential 
manner, especially with the new caller id, b) inaccurate phone numbers and/or addresses 
given by the clients, c) the transient nature of cUents, as well as d) clients who do not 
return for treatment when notified, having a rapid stat test, whereby results can be 
available (in < 30 minutes) while the client is still in the clinic, would be a major 
advantage. This would facilitate providers in prescribing immediate treatment based on a 
more definitive diagnosis as opposed to treatment based on a presumptive diagnosis, or 
delaying treatment while chlamydia results are pending. The current rapid stat test, 
however, detects all three chlamydia species, has a high false-positive rate, and has a 
sensitivity of only 48.5% (Hook HI, Spitters, Reichart, Neumann & Quinn, 1994).
Although several high risk factors have been identified, no one factor or group of 
factors has been found to be a reliable positive predictor for chlamydia. Unfortunately, 
most of the risk factors are based on client self-report of their own behavior as well as 
their knowledge of and willingness to report their partner's behavior over the past six 
months. For example, clients are asked a)"Have you had a new sexual partner?" b)"Have 
you had more than one partner?" c)"Has your partner had more than one partner?" and 
d)"Have you or your partner had a positive test for gonorrhea or an unusual discharge?" 
Sharing such confidential information with virtual strangers is fi'equently difihcult for some 
and unthinkable for others. If there was some way to elicit more reliable responses fi'om 
clients, it would most likely increase the positive predictive values of the current risk 
factor criteria. Establishing a more trusting climate, whereby the client is able to share
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sensitive information more openly, whether it is written or verbal, is the crucial first step. 
Some clients may be willing to share the requested information but may not be reliable 
because th ^  have not discussed these issues with their partner(s), or their partners have 
not been truthful with them. Encouraging clients to establish better communication 
between them and their partners, so that they are more knowledgeable about their 
partners, is another necessary step. The third step is to reduce the cost of testing so that it 
is available to all sexually active clients as part of their routine gynecological examination. 
Doing so would minimize the risk of developing complications of an untreated chlamydial 
infection. The fourth step is to follow up on client contacts, as recommended by the CDC 
(1993), so that asymptomatic partners do not go untreated and unknowingly spread the 
infection to others.
Theoretical and Clinical Implications for Nursing
Extensive selective screening studies have been done, and several high risk factors 
have been identified for the chlamydial infection. Betty Neuman's concept of primary 
prevention as intervention can, therefore, be used as a basis for educating the public in 
general and the client in particular about risk reduction methods. Primary prevention 
focuses on the protection of the flexible line of defense fi'om invasion by a stressor such as 
Chlamydia trachomatis. The challenge to health professionals is to a) provide education 
as needed, b) activate client acceptance and/or motivation, and c) assist clients in 
developing or mobilizing skills needed to negotiate parmer cooperation in utilizing primary 
prevention measures. For example, maintaining a mutually monogamous relationship 
and/or the consistent use of condoms are the primary means of risk reduction for
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chlamydia and other STD's. Therefore, the more effective health professionals are in 
assisting clients to utilize these primary preventive measures, the greater impact they will 
have in reducing the prevalence rate of chlamydia. In line with Neuman's primary 
prevention model, many states have mandated low income family planning and STD clinic 
services for local communities. Providing fiedble hours and user Mendly clinic services 
will enhance the clients desire and willingness to use them when needed. Neuman's 
secondary prevention as intervention focuses on early detection of diseases, such as 
chlamydia, and provides for treatment prior to or at the early onset of symptoms.
Universal and selective screening can be utilized to detect sexually transmitted diseases 
prior to the onset of symptoms. Selective screening can be used to detect chlamydia and 
provide treatment when symptoms first occur. Because chlamydia has been labeled the 
silent STD, selective screening for contact follow-ups is the best means for early treatment 
of asymptomatic partners. Neuman's Systems Model can be effectively used by health care 
professionals in developing services for the prevention, early detection and treatment of 
chlamydia and other sexually transmitted diseases.
Chlamydial trachomatis is a bacterial infection that can be easily treated with one oral 
dose of Azithromycin or by taking Doxycycline twice a day for seven days. Therefore, it is 
up to all health care providers to offer screening and treatment to their sexually active 
clients. Universal screening is recommended if their site prevalence rate is >5%, and 
selective screening if their prevalence rate is < 5%. Failure to do so places clients at undo 
risk, and the money saved by failing to screen clients will be lost in treating clients who 
experience complications such as FID or infertility.
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As a result of this study, the NCchigan Department of Community Health approved 
universal screening at Site A, which is currently in effect. This decision was based on 
Site A's high prevalence rate of 12.8%, as compared to the 1994 local out county and 
state prevalence rates of 7.9% and 5.08% respectively. Selective screening was 
subsequently resumed at the low prevalence Sites B & C.
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APPENDIX A 
Human Research Review
kGRAND 
IVStUUEY 
_  'STATE 
UNIVERSITY
1 CAMPUS OMVe •  ALLENOALE •
September 9, 1996
Verneal Y. Glispie 
19591 Nadol Drive 
Southfield. M I 48075
Dear Verneal;
The Human Research Review Committee o f Grand Valley State University is charged 
to examine proposals with respect to protection of human subjects. The Committee 
has considered your proposal. "Chiamydia Screening: Universal vs. Selective 
Screening P rotocor, and is satisfied that you have complied with the intent o f the 
regulations published in the Federal Register 46 (16): 8386-8392. January 26, 1981.
Sincerely.
c A -eO
Howard Stein. Acting Chair 
Human Research Review Committee
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APPENDIX B
Wayne County Department of Health (Page i of 2)
Location:
 I) Highland Park Client ID#_________________
_2) Sumpter
_3) Westland Date_____________________
Chlamydia Risk Assessment
This infonnatioa is completely voluntary and strictly confidential. It will not be 
part of your medical record here. This information will be helpful for statistical and 
planning purposes. Do not write your name on this sheet.
1) City of residence;______________________ Zip Code_____________________.
2) Type of visit: (I) Initial , (2) Annual________ , (3) Other
3) Age: , Birth date:______________________________
4) Race/Ethnicity (I) Black , (2) White , (3) American Indian
(4) Asian/Pacific Islander , (S)Alaskan Native , (6)) Hispanic
(7) Arabic , (8) Other___________________________ .
5) Highest grade completed: (I) Less than 8th , (2) 8th-llth______
(3) High School Grad_______, (4) Some College______ , (5) College Grad
6) What percentage of your family planning bill are you expected to pay? Ask clerk 
(1) 0% (2) 20%___ , (3) 40% (4) 60%___, (5) 80% , (6) 100%___.
7) Marital Status:
(1) Single (not living with partner) , (2) Single (living with partner)_______ ,
(3) Married , (4) Separated , (5) Divorced_______ ,(6)Widowed____ .
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Appendix B (continued) (Page 2 of 2)
8) Have you had a new sexual partner in the last six months?—  (0) No (1) Yes__
9) Have you had more than one sex partner in the last six months? (0) No_, (l)Yes_
10) Has a partner of yours had more than one partner in the last six months?-------------
-------------------------------- (0) No , (1) Yes , (2) Dont know______
11) Have you or a partner had a positive test for gonorrhea in the last six months?-----
----------------------------------- (0) N o , (1) Yes , (2) Don’t know______
12) Do you or a partner have an unusual discharge?----------- (0) No (1) Yes____
13) In the last six months, have you ever had sexual intercourse without using a
condom?------------------------------------------------------------(0) No____(1) Yes___
14) Do you have frequent, burning, or painful urination ? — (0) N o (1) Yes___
15) Do you have lower abdominal or pelvic pain ? ------------- (0) No (1) Yes_____
16) Have you used any type of antibiotics, vaginal creams, jellies, suppositories or
douches in the past 48 hours? (0) No (1) Yes____
If you have any additional questions or concerns, you may discuss them 
with the staff during your visit today. Please return this sheet to one of the health 
care providers today. Thank you for helping us to help you.
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!STOP HERE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Interviewing Nurse______________________________
**T0 BE RECORDED BY Physician/Nurse Practitioner;
**17) Mucopurulent discharge present? ____________ (0) No (1) Yes____
**18) Friable cervix ? ------------------------------------------------- (0) N o___ (1) Yes____
19) RESULTS of chlamydia test-------------------- ( 0) Negative___ (I) Positive___
20) Risk le v e l --------------------------------------------------- ( 1 ) Low___(2) IBgh 
VYGAKAT/D4/9
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APPENDIX C
Comparison of Chlamydia Risk Factor Prevalence Across Sites
Site A n = 47 SiteB n = 59 SheC  n  =  297 All Sites N=403
Sex V^thout Condoms Yes (27) 57.4% (47) 79.7% (216) 73.2% (290) 72.3%
No (20) 42.6% (12) 20.3% (79) 26.8% (111) 27.7%
Missing Cases (2)
New partner Yes (11) 23.4% (9) 15.3% (63) 21.3% (83) 20.6%
No (36) 76.6% (50) 84.7% (233) 78.7% (319) 79.4%
Missing Cases (I)
Multiple Partners (n^)
Yes
(9) 19.1% (4) 6.8% (36) 12.1% (49) 12.2%
No (38) 80.9% (55) 93.2% (261) 87.9% (354) 87.8%
Missing Cases (0)
Partner with mp Yes (5) 10.6% (1) 1.8% (21) 7.1% (27) 6.8%
No (31) 66.0% (47) 85.5% (222) 75.5% (300) 75.8%
D ont Know (11) 23.4% (7) 12.7% (51) 17.3% (69) 17.4%
Missing Cases (7)
Unusual discharge Yes (11) 23.4% (6) 10.3% (25) 8.4% (42) 10.5
No (36) 76.6% (52) 89.7% (271) 91.6% (359) 89.5%
Missing Cases (2)
Abdominal / Pelvic pain Yes (11) 23.4% (8) 13.6% (48) 16.2% (67) 16.6%
No (36) 76.6% (51) 86.4% (249) 83.8% (336) 83.4%
Missing Cases (0)
Antibiotics, vaginal meds, 
or douching <48 hours Yes (7) 14.9% (4) 6.9% (31) 10.5% (42) 10.5%
No (40) 85.1% (54) 93.1% (264) 89.5% (358) 89.5%
Missing Cases (3)
Mucopurulent cervicitis Yes (7) 14.9% (5) 8.5% (11) 3.7% (23) 5.7%
Missing Cases (4) No (40) 85.1% (54) 91.5% (286) 96.3% (380) 94.3%
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APPENDIX D 
Risk Factors for Clients With Chlamydia
Site A 
n = 6
SiteB 
n =  1
SiteC 
n = 5
ALL SITES 
N= 12
New partner < 6 months (2) 33.3% (1) 100% (2) 50%
1 missing case
(5) 45.5%
Multiple partners (mp ) 
< 6 months (2) 33.3% (0) (1) 20% (3) 25.0%
Partner with mp
Yes (1) 17% (0) (1) 20% (1) 9.1%
Don"t know (2) 33.3% (0) (1) 25%
1 missing case
(4) 36.4%
Gonorrhea - self or 
partner tx < 6 months
Yes (1) 17% (0) (0) (1) 8.3%
Don"t know (1) 17% (0) (1) 20% (2) 16.7%
Unusual discharge (2) 33.3% (0) (0) (2) 16.7%
Sex without condoms
No (1) 16.7% (0) 0% (0) 0% (1) 8.3%
Yes (5) 83.5% (1) 100% (5) 100% (11)91.7%
Pain, burning or 
frequency of urination (0) (0) (0) (12) 100%
Abdominal/pelvic pain (1) 17% (0) (0) (1) 8.3%
Antibiotics, vaginal meds, 
or douching <48 hours
(1) 17% (0) (1) 25% 
1 missing case
(2) 18.2%
Mucopurulent cervicitis 
(MPC) (1) 17% (0) (0) (1) 8.3%
Friable cervix (0) (1) 100% (1)20% (2) 16.7%
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APPENDIX E
Items Comprising the VD Education HBM Scale Dimensions
(Each item rated along a 5-point scale from Strongly Agree to Strongly Disagree)
1) Strongly Agree 2) Agree 3) Unsure 4) Disagree 5) Strongly Disagree
Susceptibility Scale
1 .1 cannot contract VD because I/my sexual partner(s) douche after sexual intercourse.
2 .1 am too young to have venereal disease.
3 .1 am very healthy so my body can fight off venereal disease.
4 .1 take a bath every day with soap and water, so I am not likely to catch venereal 
disease.
5 .1 cant catch venereal disease because I always use a clean toilet seat.
6. My religious teaching has been very good, so I cannot contract venereal disease.
7. My sexual partner(s) has/have resistance to venereal disease, so I cannot get VD.
8 .1 caimot contract VD because my sexual partner(s) use the pill (oral contraceptive).
9. People like me dont get VD.
10.1 cannot contract VD because my sexual partner(s) is/are always very clean.
11. If I had a venereal disease and got treated, I could not contract it again.
12. If I had syphilis, I could not have gonorrhea at the same time.
Seriousness Scale
1 .1 think gonorrhea is a serious disease because it may damage my heart in the long run.
2. An attack of gonorrhea might make me unable to have children.
3. Venereal disease is more serious than most other diseases.
4. In my opinion gonorrhea is a serious disease because it may eventually cause arthritis.
5 .1 dont believe that VD is a serious disease because it is not going to kill me.
6. Contracting VD will disturb my peace of mind.
7. If I contracted VD, it would seriously disturb my family relations.
Banier Scalg
1 .1 dont go for VD checkups because I am afi-aid other people in the clinic might think I 
have VD.
2 .1 am afraid of pain during VD checkups.
3 .1 don't want to go for VD checkups because the examination might show that I have 
VD.
4 .1 don't go for VD checkups because I have no time to do so.
5 .1 am embarrassed to go for VD checkups.
6 .1 dont like to go for VD checkups because Fm afraid the doctor might not be 
considerate of me.
7 .1 don't go for VD checkups because I dont know the location of VD clinics.
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Appendix E (continued)
Items Comprising the VD Education HBM Scale Dimensions
8 .1 am hesitant to go to VD clinics because the clinic workers may tell others about my 
visit.
9 .1 am unable to afford the cost of periodic VD checkups.
10. VD clinic hours are inconvenient for me.
11. If I were infected with VD, I would be reluctant to disclose the name of all my sexual 
partners to protect my privacy.
12. If I were infected with VD, I would be reluctant to disclose the name of all my sexual 
partners to protect their privacy.
Benefit Scale and Likelihood Scale
*These two scales comprise the same 14 items considered fi-om a different perspective.
* For the Benefit Scale, the items were answered in response to "How strongly do you 
agree that the following actions are useful in controlling and preventing venereal 
disease?"
* For the Likelihood Scale the items were answered in response to "How likely are you 
are you to take the following actions in order to prevent the control of venereal 
disease?"
1. Refusing sexual activities with casual sexual partners who would not accept the use of 
a condom (rubber).
2. Avoiding sexual intercourse with persons who have many sexual partners.
3. Refusing sexual relations with anyone who I know has had VD.
4. Examining my genital area regularly for signs of VD infection.
5. Examining  regularly the genital area of my sexual partner(s) for any sign of VD 
infection.
6. Carrying a condom (rubber) at all times for use whenever I have sexual intercourse 
with a casual sexual partner.
7. Seeking immediate medical advice if I suspect that I have contracted a venereal 
disease.
8. Telling my sexual partner(s) if I suspect that I have VD.
9. Washing the genital area with soap and water immediately after sexual intercourse.
10. Releasing the names of all my sexual contacts to the VD clinic authorities if I am 
diagnosed as having VD.
11. If infected with VD, avoiding sexual activities (even after treatment) until the cure is 
verified by a physician.
12. Encouraging anyone I suspect of having VD to seek immediate medical help.
13. Getting regular VD  checkups a minimum of four times a year for early diagnosis of the 
disease.
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Appendix £  (continued)
Items Comprising the VD Education HBM Scale Dimensions
14. Encouraging my fiiends who are sexually active to have regular VD checkups a 
minimum of four times a year.
Source; Simon, K. & Das, A. (1984). An application of the Health Belief Model toward 
educational diagnosis for VD education. Health Education Ouarterlv. 415-416.
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